Is Royalty Pharma (RPRX) Still Attractive After A 35% One Year Share Price Gain [Yahoo! Finance]
Royalty Pharma (NASDAQ:RPRX) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating.
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential [Yahoo! Finance]
Royalty Pharma (NASDAQ:RPRX) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Jim Cramer on Royalty Pharma: “It's a Terrific Company” [Yahoo! Finance]